Today we had in-depth discussions with our Chinese partners on regulatory pathways and market entry strategies in China.
We all recognize the clinical importance and value of S&T BioMed’s technology, and through collaboration and shared insights, we aim to bring this innovative solution to China and support early detection of oral cancer.